Lixte Historical Balance Sheet

LIXTW Stock

USD 0.03 0 21.30%

Trend analysis of Lixte Biotechnology Holdings balance sheet accounts such as Total Stockholder Equity of 4.2 M provides information on Lixte Biotechnology's total assets, liabilities, and equity, which is the actual value of Lixte Biotechnology to its prevalent stockholders. By breaking down trends over time using Lixte Biotechnology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Lixte Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lixte Biotechnology is a good buy for the upcoming year.

Lixte Biotechnology Inventory

58,117.4

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Lixte Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lixte Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Lixte Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lixte Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lixte currently owns. An asset can also be divided into two categories, current and non-current.

Lixte Biotechnology Balance Sheet Chart

At this time, Lixte Biotechnology's Total Stockholder Equity is fairly stable compared to the past year. Cash is likely to climb to about 4.4 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 171.6 K in 2024.

Total Assets Other Current Liab Total Current Liabilities Cash And Short Term Investments Total Liab

Total Assets

Total assets refers to the total amount of Lixte Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lixte Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lixte Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lixte Biotechnology Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Lixte Biotechnology balance sheet. This account contains Lixte Biotechnology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lixte Biotechnology Holdings fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from Lixte Biotechnology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	302.9K	394.8K	313.9K	171.6K
Total Assets	5.1M	5.6M	4.3M	2.2M

Other Current Liab Total Assets

Lixte Biotechnology balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Current Assets	Property Plant And Equipment Gross	Short Long Term Debt Total	Short Term Debt	Short Term Investments	Net Receivables	Inventory	Current Deferred Revenue	Capital Surpluse
Total Assets		0.65	0.24	0.96	-0.97	-0.76	0.95	0.96	0.73	-0.28	0.76	0.24	1.0	-0.3	-0.32	0.46	0.81	-0.34	-0.32	-0.11	0.91	-0.11	-0.66	0.4	0.35	0.92
Other Current Liab	0.65		0.46	0.63	-0.63	-0.72	0.63	0.64	0.54	0.03	0.7	0.46	0.65	-0.19	-0.3	0.41	0.68	-0.5	-0.3	-0.23	0.75	0.18	-0.47	0.42	0.72	0.7
Total Current Liabilities	0.24	0.46		0.21	-0.22	-0.45	0.22	0.23	0.26	0.18	0.43	1.0	0.24	0.13	-0.79	0.66	0.33	-0.21	-0.79	-0.12	0.25	0.33	-0.01	0.71	0.48	0.22
Total Stockholder Equity	0.96	0.63	0.21		-1.0	-0.84	1.0	1.0	0.83	-0.31	0.86	0.21	0.96	-0.4	-0.3	0.42	0.8	-0.38	-0.3	-0.35	0.88	-0.14	-0.71	0.32	0.34	0.92
Net Debt	-0.97	-0.63	-0.22	-1.0		0.83	-1.0	-1.0	-0.81	0.31	-0.85	-0.22	-0.97	0.38	0.3	-0.43	-0.79	0.42	0.3	0.32	-0.89	0.17	0.72	-0.33	-0.34	-0.92
Retained Earnings	-0.76	-0.72	-0.45	-0.84	0.83		-0.84	-0.84	-0.86	0.35	-0.99	-0.45	-0.75	0.38	0.48	-0.51	-0.73	0.28	0.48	0.59	-0.72	0.08	0.71	-0.55	-0.69	-0.87
Cash	0.95	0.63	0.22	1.0	-1.0	-0.84		1.0	0.82	-0.31	0.86	0.22	0.95	-0.39	-0.3	0.43	0.79	-0.43	-0.3	-0.36	0.88	-0.17	-0.72	0.32	0.33	0.92
Cash And Short Term Investments	0.96	0.64	0.23	1.0	-1.0	-0.84	1.0		0.83	-0.28	0.86	0.23	0.96	-0.4	-0.31	0.44	0.79	-0.42	-0.31	-0.36	0.88	-0.13	-0.71	0.33	0.33	0.92
Common Stock Total Equity	0.73	0.54	0.26	0.83	-0.81	-0.86	0.82	0.83		-0.2	0.89	0.26	0.73	-0.77	-0.2	0.31	0.86	-0.34	-0.2	-0.6	0.77	-0.08	-0.56	0.29	0.48	0.86
Common Stock Shares Outstanding	-0.28	0.03	0.18	-0.31	0.31	0.35	-0.31	-0.28	-0.2		-0.33	0.18	-0.28	-0.01	0.01	0.04	-0.18	-0.2	0.01	0.1	-0.1	0.78	0.37	-0.03	-0.31	-0.26
Other Stockholder Equity	0.76	0.7	0.43	0.86	-0.85	-0.99	0.86	0.86	0.89	-0.33		0.43	0.76	-0.44	-0.46	0.46	0.75	-0.31	-0.46	-0.64	0.74	-0.08	-0.68	0.51	0.65	0.87
Total Liab	0.24	0.46	1.0	0.21	-0.22	-0.45	0.22	0.23	0.26	0.18	0.43		0.24	0.13	-0.79	0.66	0.33	-0.21	-0.79	-0.12	0.25	0.33	-0.01	0.71	0.48	0.22
Total Current Assets	1.0	0.65	0.24	0.96	-0.97	-0.75	0.95	0.96	0.73	-0.28	0.76	0.24		-0.29	-0.32	0.46	0.81	-0.34	-0.32	-0.1	0.91	-0.11	-0.66	0.39	0.34	0.91
Common Stock	-0.3	-0.19	0.13	-0.4	0.38	0.38	-0.39	-0.4	-0.77	-0.01	-0.44	0.13	-0.29		-0.35	0.16	-0.62	0.32	-0.35	0.51	-0.45	0.12	0.18	0.19	-0.21	-0.49
Property Plant And Equipment Net	-0.32	-0.3	-0.79	-0.3	0.3	0.48	-0.3	-0.31	-0.2	0.01	-0.46	-0.79	-0.32	-0.35		-0.55	-0.17	-0.1	1.0	0.12	-0.22	-0.27	0.11	-0.87	-0.29	-0.25
Accounts Payable	0.46	0.41	0.66	0.42	-0.43	-0.51	0.43	0.44	0.31	0.04	0.46	0.66	0.46	0.16	-0.55		0.4	-0.13	-0.55	0.0	0.29	0.31	-0.54	0.44	0.29	0.39
Non Current Assets Total	0.81	0.68	0.33	0.8	-0.79	-0.73	0.79	0.79	0.86	-0.18	0.75	0.33	0.81	-0.62	-0.17	0.4		-0.38	-0.17	-0.18	0.83	-0.06	-0.51	0.23	0.51	0.82
Other Current Assets	-0.34	-0.5	-0.21	-0.38	0.42	0.28	-0.43	-0.42	-0.34	-0.2	-0.31	-0.21	-0.34	0.32	-0.1	-0.13	-0.38		-0.1	0.27	-0.49	0.17	0.27	0.03	-0.09	-0.38
Property Plant And Equipment Gross	-0.32	-0.3	-0.79	-0.3	0.3	0.48	-0.3	-0.31	-0.2	0.01	-0.46	-0.79	-0.32	-0.35	1.0	-0.55	-0.17	-0.1		0.12	-0.22	-0.27	0.11	-0.87	-0.29	-0.25
Short Long Term Debt Total	-0.11	-0.23	-0.12	-0.35	0.32	0.59	-0.36	-0.36	-0.6	0.1	-0.64	-0.12	-0.1	0.51	0.12	0.0	-0.18	0.27	0.12		-0.18	0.08	0.3	-0.14	-0.3	-0.35
Short Term Debt	0.91	0.75	0.25	0.88	-0.89	-0.72	0.88	0.88	0.77	-0.1	0.74	0.25	0.91	-0.45	-0.22	0.29	0.83	-0.49	-0.22	-0.18		-0.08	-0.53	0.33	0.47	0.9
Short Term Investments	-0.11	0.18	0.33	-0.14	0.17	0.08	-0.17	-0.13	-0.08	0.78	-0.08	0.33	-0.11	0.12	-0.27	0.31	-0.06	0.17	-0.27	0.08	-0.08		0.17	0.22	-0.06	-0.08
Net Receivables	-0.66	-0.47	-0.01	-0.71	0.72	0.71	-0.72	-0.71	-0.56	0.37	-0.68	-0.01	-0.66	0.18	0.11	-0.54	-0.51	0.27	0.11	0.3	-0.53	0.17		-0.16	-0.3	-0.72
Inventory	0.4	0.42	0.71	0.32	-0.33	-0.55	0.32	0.33	0.29	-0.03	0.51	0.71	0.39	0.19	-0.87	0.44	0.23	0.03	-0.87	-0.14	0.33	0.22	-0.16		0.46	0.43
Current Deferred Revenue	0.35	0.72	0.48	0.34	-0.34	-0.69	0.33	0.33	0.48	-0.31	0.65	0.48	0.34	-0.21	-0.29	0.29	0.51	-0.09	-0.29	-0.3	0.47	-0.06	-0.3	0.46		0.51
Capital Surpluse	0.92	0.7	0.22	0.92	-0.92	-0.87	0.92	0.92	0.86	-0.26	0.87	0.22	0.91	-0.49	-0.25	0.39	0.82	-0.38	-0.25	-0.35	0.9	-0.08	-0.72	0.43	0.51

Click cells to compare fundamentals

Lixte Biotechnology Account Relationship Matchups

Lixte Biotechnology balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Current Liab	237.9K	10.5K	302.9K	394.8K	313.9K	171.6K
Total Current Liabilities	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Stockholder Equity	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M
Net Debt	(2.6M)	(5.1M)	(4.8M)	(5.4M)	(4.2M)	(4.0M)
Retained Earnings	(27.1M)	(30.4M)	(37.1M)	(43.4M)	(48.5M)	(46.1M)
Cash	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Cash And Short Term Investments	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Common Stock Shares Outstanding	1.1M	1.1M	1.3M	158.2K	1.9M	1.8M
Liabilities And Stockholders Equity	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Stockholder Equity	26.0M	31.9M	38.4M	45.1M	49.0M	51.4M
Total Liab	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Current Assets	2.7M	5.2M	5.1M	5.6M	4.2M	2.2M
Accounts Payable	143.5K	190.3K	226.0K	229.8K	156.8K	169.4K
Other Current Assets	58.8K	159.2K	10.2K	10.4K	27.1K	25.8K
Short Term Debt	210.9K	237.9K	302.9K	394.8K	313.9K	193.4K
Current Deferred Revenue	94.3K	15.8K	77.0K	165.0K	157.1K	81.5K
Capital Surpluse	20.0M	25.3M	26.0M	31.9M	36.6M	26.5M
Net Invested Capital	(1.1M)	1.5M	1.3M	1.7M	494.8K	317K
Net Working Capital	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lixte Historical Balance Sheet

Lixte Biotechnology Inventory

58,117.4

About Lixte Balance Sheet Analysis

Lixte Biotechnology Balance Sheet Chart

Total Assets

Total Current Liabilities

Cash And Short Term Investments

Total Liab

Lixte Biotechnology balance sheet Correlations

Lixte Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lixte Biotechnology balance sheet Accounts

Also Currently Popular

Additional Tools for Lixte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Other Stockholder Equity	- 0.99	Retained Earnings
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets